Among the 232 patients included in the study, 60 (25.9%) had HER2-zero breast cancer, 91 (39.2%) had HER2-low breast cancer, and 81 (34.9%) had HER2-overexpression breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.